FDA WARNING_LETTER - Vintage Pharmaceuticals, LLC - August 08, 2007

The FDA issued a Warning Letter to Vintage Pharmaceuticals, LLC, following a July-August 2007 inspection of their Huntsville, Alabama, facility, revealing significant violations of Current Good Manufacturing Practice (CGMP) regulations (21 CFR 210 and 211). These violations render their drug products adulterated under 21 U.S.C. 351(a)(2)(B).

Key CGMP violations include: * **Inadequate Investigation of Microbiological Contamination:** Failure to fully investigate microbial growth in pre-gelatinized starch, including incomplete records of test results, inconsistencies in retesting explanations, and an unsubstantiated conclusion regarding microorganism objectionability. * **Failure to Follow Test Procedures and Record Keeping:** Deviations from established test procedures, such as unrecorded diluent volumes, unauthorized adjustments to SOPs, and improper signing of laboratory records (relying on handwriting analysis instead of direct signatures). * **Failure to Prevent Objectionable Microorganisms:** Non-adherence to environmental monitoring SOPs, including lack of isolate identification from air samples and delayed establishment of alert/action limits. * **Unsound Test Procedures:** Inadequate preparatory testing for microbial limits for numerous drug products, failing to assure neutralization of inhibitory properties. * **Failure to Withhold Components:** Release and dispensing of a component lot for production before the investigation report was fully signed by Quality Control and other officials, and prior to